Flavin-containing monooxygenase

Flavin-containing monooxygenase

Ribbon diagram of yeast FMO (PDB: 1VQW).
Identifiers
EC number 1.14.13.8
CAS number 37256-73-8
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
Gene Ontology AmiGO / EGO
Flavin-containing monooxygenase FMO
Identifiers
Symbol Flavin_mOase
Pfam PF00743
InterPro IPR000960

The flavin-containing monooxygenase (FMO) protein family specializes in the oxidation of xeno-substrates in order to facilitate the excretion of these compounds from living organisms.[1] These enzymes can oxidize a wide array of heteroatoms, particularly soft nucleophiles, such as amines, sulfides, and phosphites. This reaction requires an oxygen, an NADPH cofactor, and an FAD prosthetic group.[2][3][4] FMOs share several structural features, such as a NADPH binding domain, FAD binding domain, and a conserved arginine residue present in the active site. Recently, FMO enzymes have received a great deal of attention from the pharmaceutical industry both as a drug target for various diseases and as a means to metabolize pro-drug compounds into active pharmaceuticals.[5] These monooxygenases are often misclassified because they share similar activity profiles with Cytochrome P450 (CYP450), which is the major contributor to oxidative xenobiotic metabolism. However, a key difference between the two enzymes lies in how they proceed to oxidize their respective substrates; CYP enzymes make use of an oxygenated heme prosthetic group, while the FMO family utilizes FAD to oxidize its substrates.

History

Prior to the 1960s, the oxidation of xenotoxic materials was thought to be completely accomplished by CYP450. However, in the early 1970s, Dr. Daniel Ziegler from the University of Texas at Austin discovered a hepatic flavoprotein isolated from pig liver that was found to oxidize a vast array of various amines to their corresponding nitro state. This flavoprotein named "Ziegler's enzyme" exhibited unusual chemical and spectrometric properties. Upon further spectroscopic characterization and investigation of the substrate pool of this enzyme, Dr. Ziegler discovered that this enzyme solely binded an FAD molecule that could form a C4a-hydroxyperoxyflavin intermediate, and that this enzyme could oxidize a wide variety of substrates with no common structural features, including phosphines, sulfides, selenium compounds, amongst others. Once this was noticed, Dr. Ziegler's enzyme was reclassified as a broadband flavin monooxygenase.[6]

In 1984, the first evidence for multiple forms of FMOs was elucidated by two different laboratories when two distinct FMOs were isolated from rabbit lungs. Since then, over 150 different FMO enzymes have been successfully isolated from a wide variety of organisms.[7] Up until 2002, only 5 FMO enzymes were successfully isolated from mammals. However, a group of researchers found a sixth FMO gene located on human chromosome 1.[8] In addition to the sixth FMO discovered as of 2002, the laboratories of Dr. Ian Philips and Elizabeth Sheppard discovered a second gene cluster in humans that consists of 5 additional pseudogenes for FMO on human chromosome 1.[9]

Evolution of FMO Gene Family

The FMO family of genes is conserved across all phyla that have been studied so far, therefore some form of the FMO gene family can be found in all studied eukaryotes. FMO genes are characterized by specific structural and functional constraints, which led to the evolution of different types of FMO's in order to perform a variety of functions. Divergence between the functional types of FMO's (FMO 1–5) occurred before the amphibians and mammals diverged into separate classes. FMO5 found in vertebrates appears to be evolutionarily older than other types of FMO's, making FMO5 the first functionally distinct member of the FMO family. Phylogenetic studies suggest that FMO1 and FMO3 are the most recent FMO's to evolve into enzymes with distinct functions. Although FMO5 was the first distinct FMO, it is not clear what function it serves since it does not oxygenate the typical FMO substrates involved in first-pass metabolism.

Analyses of FMO genes across several species have shown extensive silent DNA mutations, which indicate that the current FMO gene family exists because of selective pressure at the protein level rather than the nucleotide level. FMO's found in invertebrates are found to have originated polyphyletically; meaning that a phenotypically similar gene evolved in invertebrates which was not inherited from a common ancestor.[10]

Classification and Characterization

FMOs are one subfamily of class B external flavoprotein monooxygenases (EC 1.14.13), which belong to the family of monooxygenase oxidoreductases, along with the other subfamilies Baeyer-Villiger monooxygenases and microbial N-hydroxylating monooxygenases.[11] FMO's are found in fungi, yeast, plants, mammals, and bacteria.[11][12]

Mammals

Developmental and tissue specific expression has been studied in several mammalian species, including humans, mice, rats, and rabbits.[13] However, because FMO expression is unique to each animal species, it is difficult to make conclusions about human FMO regulation and activity based on other mammalian studies.[14] It is likely that species-specific expression of FMO's contributes to differences in susceptibility to toxins and xenobiotics as well as the efficiency with excreting among different mammals.[13]

Six functional forms of human FMO genes have been reported. However, FMO6 is considered to be a pseudogene.[15] FMOs 1–5 share between 50–58% amino acid identity across the different species.[16] Recently, five more human FMO genes were discovered, although they fall in the category of pseudogenes.[17]

Yeast (Saccharomyces cerevisiae)

Unlike mammals, yeast do not have several isoforms of FMO, but instead only have one called yFMO. This enzyme does not accept xenobiotic compounds. Instead, yFMO helps to fold proteins that contain disulfide bonds by catalyzing O2 and NADPH-dependent oxidations of biological thiols, just like mammalian FMO's.[18][19] An example is the oxidation of glutathione to glutathione disulfide, both of which form a redox buffering system in the cell between the endoplasmic reticulum and the cytoplasm. yFMO is localized in the cytoplasm in order to maintain the optimum redox buffer ratio necessary for proteins containing disulfide bonds to fold properly.[18] This non-xenobiotic role of yFMO may represent the original role of the FMO's before the rise of the modern FMO family of enzymes found in mammals.[19]

Plants

Plant FMO's play a role in defending against pathogens and catalyze specific steps in the biosynthesis of auxin, a plant hormone. Plant FMO's also play a role in the metabolism of glucosinolates. These non-xenobiotic roles of plant FMO's suggest that other FMO functions could be identified in non-plant organisms.[20]

Structure

Crystal structures have been determined for yeast (Schizosaccharomyces pombe) FMO (PDB: 1VQW) and bacterial (Methylophaga aminisulfidivorans) FMO (PDB: 2XVH).[1][21] The crystal structures are similar to each other and they share 27% sequence identity.[22] These enzymes share 22% and 31% sequence identity with human FMOs, respectively.[1][22]

Channel and active site of bacterial FMO with bound NADPH and FAD (PDB: 2XVH).

FMOs have a tightly bound FAD prosthetic group and a binding NADPH cofactor.[11] Both dinucleotide binding motifs form Rossmann folds. The yeast FMO and bacterial FMO are dimers, with each monomer consisting of two structural domains: the smaller NADPH binding domain and the larger FAD-binding domain. The two domains are connected by a double linker. A channel between the two domains leads to the active site where NADPH binds both domains and occupies a cleft that blocks access to the flavin group of FAD, which is bound to the large domain along the channel together with a water molecule.[1][22] The nicotinamide group of NADPH interacts with the flavin group of FAD, and the NADPH binding site overlaps with the substrate binding site on the flavin group.[1]

FMOs contain several sequence motifs that are conserved across all domains:[12][20][21]

The FMO identifying motif interacts with the flavin of FAD.[1] The F/LATGY motif is a sequence motif common in N-hydroxylating enzymes.[20] The arginine residue interacts with the phosphate group of NADPH.[21]

Function

Reactions catalyzed by FMOs.

The general function of these enzymes is to metabolise xenobiotics.[16] Hence, they are considered to be xenobiotic detoxication catalysts. These proteins catalyze the oxygenation of multiple heteroatom-containing compounds that are present in our diet, such as amine-, sulfide-, phosphorus-, and other nucleophilic heteroatom-containing compounds. FMOs have been implicated in the metabolism of a number of pharmaceuticals, pesticides and toxicants, by converting the lipophilic xenobiotics into polar, oxygenated, and readily excreted metabolites.[14]

Substrate diversity

FMO substrates are structurally diverse compounds. However, they all share similar characteristics:

Zwitterions, anions and dications are considered to be unfavorable substrates. There are several drugs reported to be typical substrates for FMOs.

Typical Drug Substrates
Albendazole Clindamycin Pargyline
Benzydamine Fenbendazole Ranitidine
Chlorpheniramine Itopride Thioridazine
Cimetidine Olopatadine Sulindac sulfide
Xanomeline Zimeldine

The majority of drugs function as alternate substrate competitive inhibitors to FMOs (i.e. good nucleophiles that compete with the drug for FMO oxygenation), since they are not likely to serve as FMO substrates.[14] Only a few true FMO competitive inhibitors have been reported. Those include indole-3-carbinol and N,N-dimethylamino stilbene carboxylates.[23][24] A well-known FMO inhibitor is methimazole (MMI).

Mechanism

Catalytic cycle of FMOs together with the redox state of the FAD prosthetic group.

The FMO catalytic cycle proceeds as follows:

  1. The cofactor NADPH binds to the oxidized state of the FAD prosthetic group, reducing it to FADH2.
  2. Molecular oxygen binds to the formed NADP+-FADH2-enzyme complex and is reduced, resulting in 4a-hydroperoxyflavin (4a-HPF or FADH-OOH). This specie is stabilized by NADP+ in the catalytic site of the enzyme. These first two steps in the cycle are fast.[25][26]
  3. In the presence of a substrate (S), a nucleophilic attack occurs on the distal O-atom of the prosthetic group. The substrate is oxygenated to SO, forming the 4a-hydroxyflavin (FADH-OH). Only when the flavin is in the hydroperoxy form is when the xenobiotic substrate will react.[27]
  4. The flavin product then breaks down with release of water to reform FAD.
  5. Due to the low dissociation constant of the NADP+-enzyme complex,[28] NADP+ is released by the end of the cycle and the enzyme returns to its original state.The rate-limiting step involves either the breakdown of FADH-OH to water or the release of NADP+.[3][4]

Cellular Expression in Humans

Main distributions of different types of Flavin-containing Monooxygenases (FMO) in adult human tissues.

Expression of each type of FMO relies on several factors including, cofactor supply, physiological & environmental factors, as well as diet. Because of these factors, each type of FMO is expressed differently depending on the species and tissue.[29] In humans, expression of FMO's is mainly concentrated to the human liver, lungs, and kidneys, where most of the metabolism of xenobiotics occur. However, FMO's can also be found in the human brain and small intestine. While FMO1-5 can be found in the brain, liver, kidneys, lungs, and small intestine, the distribution of each type of FMO differs depending on the tissue and the developmental stage of the person.[14]

Expression in Adult Tissues

In an adult, FMO1 is predominately expressed in the kidneys and to a lesser extent in the lungs and small intestine. FMO2 is the most abundant of the FMO's and is mostly expressed in the lungs and kidneys, with lower expression in the liver and small intestine. FMO3 is highly concentrated in the liver, but is also expressed in the lungs. FMO4 is expressed mostly in the liver and kidneys. FMO5 is highly expressed in the liver, but also has substantial expression in the lungs and small intestine. Though FMO2 is the most expressed FMO in the brain, it only constitutes about 1% of that found in the lungs, making FMO expression in the brain fairly low.[14]

Expression in Fetal Tissues

The distribution of FMO's in various types of tissues changes as a person continues to develop, making the fetal distribution of FMO's quite different than adult distribution of FMO's. While the adult liver is dominated by the expression of FMO3 and FMO5, the fetal liver is dominated by the expression of FMO1 and FMO5. Another difference is in the brain, where adults mostly express FMO2 and fetuses mostly express FMO1.[14]

Clinical significance

Drug development

Further information: Drug development

Drug metabolism is one of the most important factors to consider when developing new drugs for therapeutic applications. The degradation rate of these new drugs in an organism’s system determines the duration and intensity of their pharmacological action. During the past few years, FMOs have gained a lot of attention in drug development since these enzymes are not readily induced or inhibited by the chemicals or drugs surrounding their environment.[14] CYPs are the primary enzymes involved in drug metabolism. However, recent efforts have been directed towards the development of drug candidates that incorporate functional groups that can be metabolized by FMOs. By doing this, the number of potential adverse drug-drug interactions is minimized and the reliance on CYP450 metabolism is decreased. Several approaches have been made to screen potential drug interactions. One of them includes human FMO3 (hFMO3), which is described as the most vital FMO regarding drug interactions. In order to successfully screen hFMO3 in a high throughput fashion hFMO3 was successfully fixed to graphene oxide chips in order to measure the change in electrical potential generated as a result of the drug being oxidized when it interacts with the enzyme.[30]

Hypertension

There is evidence that FMOs are associated to the regulation of blood pressure. FMO3 is involved in the formation of TMA N-oxides (TMAO). Some studies indicate that hypertension can develop when there are no organic osmolytes (i.e. TMAO) that can counteract an increase in osmotic pressure and peripheral resistance.[31] Individuals with deficient FMO3 activity have a higher prevalence of hypertension and other cardiovascular diseases, since there is a decrease in formation of TMA N-oxides to counterbalance the effects of a higher osmotic pressure and peripheral resistance.[32]

Fish odor syndrome

Further information: Trimethylaminuria disorder

The trimethylaminuria disorder, also known as fish odor syndrome, causes abnormal FMO3-mediated metabolism or a deficiency of this enzyme in an individual. A person with this disorder has a low capacity to oxidize the trimethylamine (TMA) that comes from their diet to its odourless metabolite TMAO.[33] When this happens, large amounts of TMA are excreted through the individual’s urine, sweat, and breath, with a strong fish-like odor. As of today, there is no known cure or treatment for this disorder. However, doctors recommend patients to avoid foods containing choline, carnitine, nitrogen, sulfur and lecithin.

Other diseases

FMOs have also been associated with other diseases, such as cancer and diabetes.[34][35] Yet, additional studies are imperative to elucidate what is the relationship between FMO function and these diseases, as well as to define these enzymes’ clinical relevance.

References

  1. 1 2 3 4 5 6 Eswaramoorthy S, Bonanno JB, Burley SK, Swaminathan S (June 2006). "Mechanism of action of a flavin-containing monooxygenase". Proceedings of the National Academy of Sciences of the United States of America 103 (26): 9832–9837. doi:10.1073/pnas.0602398103. PMC 1502539. PMID 16777962.
  2. ↑ Cashman JR (March 1995). "Structural and catalytic properties of the mammalian flavin-containing monooxygenase". Chemical Research in Toxicology 8 (2): 166–81. doi:10.1021/tx00044a001. PMID 7766799.
  3. 1 2 Poulsen LL, Ziegler DM (April 1995). "Multisubstrate flavin-containing monooxygenases: applications of mechanism to specificity". Chemico-Biological Interactions 96 (1): 57–73. doi:10.1016/0009-2797(94)03583-T. PMID 7720105.
  4. 1 2 Krueger SK, Williams DE (June 2005). "Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism". Pharmacology & Therapeutics 106 (3): 357– 387. doi:10.1016/j.pharmthera.2005.01.001. PMC 1828602. PMID 15922018.
  5. ↑ Hernandez D, Addou S, Lee D, Orengo C, Shephard EA, Phillips IR (September 2003). "Trimethylaminuria and a human FMO3 mutation database". Human Mutation 22 (3): 209–13. doi:10.1002/humu.10252. PMID 12938085.
  6. ↑ Ziegler, D (2002). "An overview of the mechanism, substrate specificities, and structure of FMOs". Drug Metabolism Reviews 34 (3): 503–511. doi:10.1081/DMR-120005650.
  7. ↑ van Berkel, W.J.H.; Kamerbeek, N.M.; Fraaije, M.W. (August 2006). "Flavoprotein monooxygenases, a diverse class of oxidative biocatalysts". Journal of Biotechnology 124 (4): 670–689. doi:10.1016/j.jbiotec.2006.03.044. PMID 16712999.
  8. ↑ Hines, RN; Hopp, KA; Franco, J; Saeian, K; Begun, FP (August 2002). "Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase.". Molecular Pharmacology 62 (2): 320–5. doi:10.1124/mol.62.2.320. PMID 12130684.
  9. ↑ Hernandez, D; Janmohamed, A; Chandan, P; Phillips, IR; Shephard, EA (February 2004). "Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters.". Pharmacogenetics 14 (2): 117–30. doi:10.1097/00008571-200402000-00006. PMID 15077013.
  10. ↑ Hao da C, Chen SL, Mu J, Xiao PG (November 2009). "Molecular phylogeny, long-term evolution, and functional divergence of flavin-containing monooxygenases". Genetica 137 (2): 173–187. doi:10.1007/s10709-009-9382-y.
  11. 1 2 3 van Berkel WJ, Kamerbeek NM, Fraaije MW (August 2006). "Flavoprotein monooxygenases, a diverse class of oxidative biocatalysts". Journal of Biotechnology 124 (4): 670–89. doi:10.1016/j.jbiotec.2006.03.044. PMID 16712999.
  12. 1 2 Chen Y, Patel NA, Crombie A, Scrivens JH, Murrell JC (October 2011). "Bacterial flavin-containing monooxygenase is trimethylamine monooxygenase". Proceedings of the National Academy of Sciences of the United States of America 108 (43): 17791–17796. doi:10.1073/pnas.1112928108. PMC 3203794. PMID 22006322.
  13. 1 2 Hines RN, Cashman JR, Philpot RM, Williams DE, Ziegler DM (1994). "The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression". Toxicol. Appl. Pharmacol. 125 (1): 1–6. doi:10.1006/taap.1994.1042. PMID 8128486.
  14. 1 2 3 4 5 6 7 Cashman JR, Zhang J (2006). "Human flavin-containing monooxygenases". Annual Review of Pharmacology and Toxicology 46: 65–100. doi:10.1146/annurev.pharmtox.46.120604.141043. PMID 16402899.
  15. ↑ Hines RN, Hopp KA, Franco J, Saeian K, Begun FP (2002). "Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase". Mol. Pharmacol. 62 (2): 320–5. doi:10.1124/mol.62.2.320. PMID 12130684.
  16. 1 2 Lawton MP, Cashman JR, Cresteil T, Dolphin CT, Elfarra AA, Hines RN, Hodgson E, Kimura T, Ozols J, Phillips IR (January 1994). "A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities". Archives of Biochemistry and Biophysics 308 (1): 254–257. doi:10.1006/abbi.1994.1035. PMID 8311461.
  17. ↑ Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA (February 2004). "Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters". Pharmacogenetics 14 (2): 117–130. doi:10.1097/00008571-200402000-00006. PMID 15077013.
  18. 1 2 Suh JK, Poulsen LL, Ziegler DM, Robertus JD (March 1999). "Yeast flavin-containing monooxygenase generates oxidizing equivalents that control protein folding in the endoplasmic reticulum". Proceedings of the National Academy of Sciences of the United States of America 96 (6): 2687–91. doi:10.1073/pnas.96.6.2687. PMC 15830. PMID 10077572.
  19. 1 2 Suh JK, Poulsen LL, Ziegler DM, Robertus JD (1996). "Molecular cloning and kinetic characterization of a flavin-containing monooxygenase from Saccharomyces cerevisiae". Arch. Biochem. Biophys. 336 (2): 268–74. doi:10.1006/abbi.1996.0557. PMID 8954574.
  20. 1 2 3 Schlaich NL (September 2007). "Flavin-containing monooxygenases in plants: looking beyond detox". Trends in Plant Science 12 (9): 412–418. doi:10.1016/j.tplants.2007.08.009.
  21. 1 2 3 Cho HJ, Cho HY, Kim KJ, Kim MH, Kim SW, Kang BS (July 2011). "Structural and functional analysis of bacterial flavin-containing monooxygenase reveals its ping-pong-type reaction mechanism". Journal of Structural Biology 175 (1): 39–48. doi:10.1016/j.jsb.2011.04.007. PMID 21527346.
  22. 1 2 3 Alfieri A, Malito E, Orru R, Fraaije MW, Mattevi A (May 2008). "Revealing the moonlighting role of NADP in the structure of a flavin-containing monooxygenase". Proceedings of the National Academy of Sciences of the United States of America 105 (18): 6572–6577. doi:10.1073/pnas.0800859105.
  23. ↑ Cashman, JR; Xiong, Y; Lin, J; Verhagen, H; et al. (September 1999). "In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 in the presence of dietary indoles". Biochem Pharmacol. 58 (6): 1047–1055. doi:10.1016/S0006-2952(99)00166-5. PMID 10509757.
  24. ↑ Clement, B; Weide, M; Ziegler, DM (1996). "Inhibition of Purified and Membrane-Bound Flavin-Containing Monooxygenase 1 by (N,N-Dimethylamino)stilbene Carboxylates". Chem. Res. Toxicol. 9 (3): 599–604. doi:10.1021/tx950145x. PMID 8728504.
  25. ↑ Ziegler, DM (1980). "Microsomal flavin-containing monooxygenase: oxygenation of nucleophilic nitrogen and sulfur compounds". Enzymatic Basis of Detoxication 1. New York: Academic Press. pp. 201–227.
  26. ↑ Ziegler, DM (1990). "Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity". Trends Pharmacol Sci. 11 (8): 321–324. doi:10.1016/0165-6147(90)90235-Z.
  27. ↑ Ziegler DM (August 2002). "An overview of the mechanism, substrate specificities, and structure of FMOs". Drug Metabolism Reviews 34 (3): 503–511. doi:10.1081/DMR-120005650.
  28. ↑ Testa B, Krämer SD (March 2007). "The biochemistry of drug metabolism—an introduction: Part 2. Redox reactions and their enzymes". Chemistry & Biodiversity 4 (3): 257–405. doi:10.1002/cbdv.200790032.
  29. ↑ Ziegler, DM; Poulsen, LL (1998). "Catalytic Mechanism of FMO-Catalyzed N- and S- Oxidations". Drug Metabolism. Towards the Next Millennium. Amsterdam: IOS Press. pp. 30–38.
  30. ↑ Castrignanò S, Gilardi G, Sadeghi SJ (February 2015). "Human Flavin-Containing Monooxygenase 3 on Graphene Oxide for Drug Metabolism Screening". Analytical Chemistry 87: 150129003646005. doi:10.1021/ac504535y. PMID 25630629.
  31. ↑ Lifton RP (May 1996). "Molecular genetics of human blood pressure variation". Science 272 (5262): 676–680. doi:10.1126/science.272.5262.676. PMID 8614826.
  32. ↑ Treacy EP, Akerman BR, Chow LM, Youil R, Bibeau C, Lin J, Bruce AG, Knight M, Danks DM, Cashman JR, Forrest SM (May 1998). "Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication". Human Molecular Genetics 7 (5): 839–845. doi:10.1093/hmg/7.5.839. PMID 9536088.
  33. ↑ "Abstracts of papers presented at the 38th European Organization for Caries Research (ORCA) Congress. Corfu, Greece, July 10–13, 1991". Caries Research 25 (3): 655–657. 1993. PMID 1678986.
  34. ↑ Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE, Hall SD (July 2000). "Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes". Biochemical Pharmacology 60 (1): 7–17. doi:10.1016/S0006-2952(00)00301-4. PMID 10807940.
  35. ↑ Wang T, Shankar K, Ronis MJ, Mehendale HM (August 2000). "Potentiation of thioacetamide liver injury in diabetic rats is due to induced CYP2E1". The Journal of Pharmacology and Experimental Therapeutics 294 (2): 473–479. PMID 10900221.

External links

This article is issued from Wikipedia - version of the Thursday, March 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.